IGEA pharma non-executive board members resigned after completion of the first post-combination phase. New members to be nominated
Hoofddorp, the Netherlands, 1February 2022. Today the Board of Directors of IGEA Pharma N.V. (SIX: IGPH) has acknowledged the resignation of Mrs Giovanna Puppo, Mr Raffaele Bertoni, Mr Lieven Baten and Mr Massimiliano Colella as members of the Board of Directors. The resignation is effective as of 31 January 2022 and is motivated by personal reasons.
Vincenzo Moccia CEO said: “IGEA is grateful for the professionalism and the great job done by all the team during the last months, assuring the company a huge support in the first delicate phase of the business combination with Blue Sky Natural Resources Ltd happened on September 2021.The company is now ready to enter the next phase focusing all the efforts on its business goals”.
IGEA has already identified candidates to be nominated in the next General Shareholders Meeting.
IGEA Pharma N.V. focuses through its Joint Venture on industrial CO2 supercritical extraction of CBD and other valuable components from their vegetable matrices for health prevention, pharma, food&beverage and other selected industries, with an innovative early-stage commercial and highly diversifiable pipeline. The company aims to become a center of excellence on highly controlled vegetable matrices and their industrial extraction technology. On the other hand, Igea operates on preventative health-tech products and devices, commercializing an Alzheimer’s prevention set (which includes ’Alz1’, an at-home lab test kit to measure non-bound copper in the blood and a natural dietary supplement branded ‘Alz1 Tab’ designed to reduce blood heavy metals content) and expects to integrate the non-bound copper detection-based pipeline with a diabetes type II prevention set in the next future. IGEA furthermore commercializes a COVID19 rapid test for the detection of IgM and IgG SARSCoV-2 related antibodies.
IGEA is listed on the SIX Swiss Exchange (ticker IGPH) and is headquartered in Hoofddorp, the Netherlands. Find out more at www.igeapharma.nl
Vincenzo Moccia, CEO, +39 340 583 09 33, email@example.com
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in IGEA. The information contained in this press release has been carefully prepared. However, IGEA bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. IGEA does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons. This publication may contain specific forward-looking statements and assessments or intentions concerning IGEA and its business. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development, or performance of IGEA and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties, readers should not rely on forward-looking statements. IGEA assumes no responsibility to update forward looking statements or to adapt them to future events or developments, except as may be required by law.